60 reports

Cancer is one of the major factors for mortality and morbidity globally.

  • Cancer
  • World
  • Forecast
  • Market Size
  • Celgene Corporation
  • LUNG CANCER THERAPEUTICS MARKET IN EMEA
  • MARKET PENETRATION OF VARIOUS LUNG CANCER THERAPEUTICS MANUFACTURERS IN GLOBAL (2015)

About Lung Cancer Therapeutics Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Smoking is a major cause of lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two major types, namely NSCLC and SCLC. NSCLC is the commonest type of lung cancer and constitutes...

  • Cancer
  • Lung Cancer
  • Therapy
  • AstraZeneca PLC
  • Celgene Corporation
  • 11.1 BIBLIOGRAPHY
  • 8.1 OVERVIEW OF R&D STRATEGIES

ET AL. (2014) ' CANCER STATISTICS, 2014', CA: A CANCER JOURNAL FOR CLINICIANS, ##(##), PP. ##-##.

  • Cancer
  • Hospital
  • Pancreatic Cancer
  • Therapy
  • Celgene Corporation
  • HEMATOLOGICAL CANCERS THERAPEUTICS MARKET, GLOBAL, COMPANIES BY COMPOUND
  • HEMATOLOGICAL CANCERS THERAPEUTICS MARKET, GLOBAL, CLUSTER BY GROWTH AND

Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market Summary Hematological malignancies are a class of cancer that affect the blood, lymph nodes and bone marrow. They include numerous forms of leukemia, lymphoma and myeloma. Hematological...

  • Cancer
  • Leukemia
  • World
  • Celgene Corporation
  • Idera Pharmaceuticals, Inc.
  • Non-hematological Cancer, Global, Key Marketed Products and Approved Indications, 2015
  • 5 Multi-scenario Market Forecast to 2021

Global Non-Hematological Cancers Market to 2021 - Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics Summary In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis, non-hematological cancers are thought to account for 94% of...

  • Cancer
  • Oncology
  • Therapy
  • Celgene Corporation
  • Idera Pharmaceuticals, Inc.
  • Market Drivers / Barriers
  • NOVEL TREATMENT RESEARCH ACTIVITIES

This report, the World Market for Cancer Therapeutics presents a detailed picture of the market for cancer drugs, with a focus on novel therapies. The market analysis in this report includes analysis of products avaiable for each cancer type (Breast Cancer, Lung Cancer, Prostate Cancer, Stomach Cancer, Lymphoma, Colon Cancer and Other types)...

  • Cancer
  • Targeted Therapy
  • Therapy
  • Celgene Corporation
  • Novartis AG
  • C) Treatment population
  • 8.1 BIBLIOGRAPHY

Cancer Discovery; ##(##): ##-## Hanahan D and Weinberg RA (2011).

  • Cancer
  • World
  • Market Size
  • Celgene Corporation
  • Idera Pharmaceuticals, Inc.
  • Hematological Cancers Therapeutics Market, Global, First-in-Class Products in Clinical Development, Part 1, 2016
  • Hematological Cancers Therapeutics Market, Global, First-in-Class Products in Clinical Development, Part 3, 2016

Frontier Pharma: Hematological Cancers - Highly Innovative Pipeline Continues Trend towards Targeted, Patient-Specific Therapies Summary Hematological malignancies are a class of cancer that affect the blood, lymph nodes and bone marrow, and include numerous forms of leukemia, lymphoma and myeloma. Hematological...

  • Cancer
  • World
  • Market Size
  • Celgene Corporation
  • Idera Pharmaceuticals, Inc.
  • MARKET ANALYSIS 2014
  • Vendor landscape

ACCORDING TO THE AMERICAN LUNG ASSOCIATION, LUNG CANCER IS ONE OF THE LEADING CAUSE OF DEATH BY CANCER IN THE US.

  • Cancer
  • Lung Cancer
  • Therapy
  • AstraZeneca PLC
  • Celgene Corporation
  • Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Pipeline for Hematological Cancers
  • Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Pipeline for Hematological Cancers

Frontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline Summary Hematological cancer describes a group of malignancies that affect the blood, lymph nodes and bone marrow. The three main types are leukemia,...

  • Cancer
  • Leukemia
  • Therapy
  • Celgene Corporation
  • Novartis AG
  • Cancer Metabolism Based Therapeutics: Distribution by Key Players
  • 8.3. CANCER METABOLISM BASED THERAPEUTICS: RECENT PARTNERSHIPS

INTRODUCTION Cancer metabolism is based on the principle that cancer cells, as compared to normal cells, have different metabolic activities in order to support their enhanced energy and anabolic requirements. The pioneering discovery by Otto Warburg in the middle of the 20th century led to the observation that metabolic activity...

  • Cancer
  • Pharmaceutical
  • Therapy
  • Celgene Corporation
  • Polaris Pharmaceuticals, Inc.
  • Global HER-2 Positive Breast Cancer Market
  • 08.3 HER-2 POSITIVE BREAST CANCER MARKET IN US

About HER-2 Positive Breast Cancer Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated...

  • Breast Cancer
  • Cancer
  • Therapy
  • United States
  • Celgene Corporation
  • Zarour HM, et al. (2003). Categories of tumor antigens. Cancer Medicine; 6th Edition
  • 3.7 IMFINZI (DURVALUMAB) - ASTRAZENECA/CELGENE

Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline Summary Cancer immunotherapy, which can predominantly be classed as a form of targeted therapy, drives an immune response against cancer cells. This...

  • Cancer
  • Cancer Immunotherapy
  • Therapy
  • Celgene Corporation
  • Idera Pharmaceuticals, Inc.

Pancreatic cancer

4385 5000 3900
  • Forecast: Pancreatic Cancer
  • Marketed Drugs: Pancreatic Cancer

The prognosis of patients with pancreatic cancer remains poor; however, this clinical need will drive future market expansion and the development of several targeted therapies. This report addresses the following questions: -What are the current treatment options for patients with pancreatic cancer in each therapeutic...

  • Cancer
  • Obesity
  • Pancreatic Cancer
  • Therapy
  • Celgene Corporation
  • Pipeline: Triple-Negative Breast Cancer
  • Marketed Drugs: Triple-Negative Breast Cancer

The aggressive nature of triple-negative breast cancer and a lack of targeted therapies creates opportunities for pipeline candidates to fulfil areas of high unmet need. This report addresses the following questions: - Which branded therapies will have the largest commercial potential in the triple-negative breast cancer...

  • Breast Cancer
  • Cancer
  • Targeted Therapy
  • Therapy
  • Celgene Corporation
  • PANCREATIC CANCER THERAPEUTICS, GLOBAL, DEVELOPMENTAL PIPELINE, PHASE I, 2015
  • 8.3 References

Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape Summary Pancreatic Cancer (PC) is a disease predominately of the elderly with ~75% of PC cases being diagnosed in patient’s over 75 years old. PC proliferates rapidly, is...

  • Cancer
  • Clinical Trial
  • Pancreatic Cancer
  • Therapy
  • Celgene Corporation
  • Global pancreatic cancer drugs market
  • Scope of the report

About the Solid Tumors Drugs Market The rising prevalence of various cancers, which has led to innovations and technological advancements, drives the development of new immunotherapy drugs that are more effective than the available drugs to treat solid tumors. Solid tumors are an abnormal mass of tissue that do not contain cysts...

  • Breast Cancer
  • Cancer
  • Therapy
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • Lymphoma drugs market in Americas
  • Lymphoma drugs market in EMEA

Lymphoma is one of the most prevalent forms of cancers, affecting huge population every year.

  • Cancer
  • Lymphoma
  • United States
  • Forecast
  • Celgene Corporation
  • ONCOLOGY, GLOBAL, KEY MARKETED PRODUCTS AND APPROVED INDICATIONS, 2017

Cancer Control; ##(##): ##-##.

  • Cancer
  • Oncology
  • Therapy
  • Celgene Corporation
  • Idera Pharmaceuticals, Inc.
  • 07.1 MARKET OVERVIEW
  • 18.1 COMPETITIVE SCENARIO

About HER-2 Positive Breast Cancer Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated...

  • Cancer
  • United States
  • Market Segment
  • Market Size
  • Celgene Corporation
  • CAR-T
  • 18. APPENDIX 2: TABULATED DATA

INTRODUCTION Amidst the current initiatives to develop more targeted anti-cancer therapies, chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a potent and viable therapeutic intervention to eradicate tumor cells, with minimal side effects. It is based on the principle of harnessing the innate potential of...

  • Automotive
  • Cancer
  • Motor Vehicle
  • Therapy
  • Celgene Corporation
  • Chapter 7: Pipeline Disruptors: Leukemia

LUNG CANCER HAS ONE OF THE HIGHEST INCIDENCES WITH ONE OF THE HIGHEST MORTALITY RATES.

  • Cancer
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Celgene Corporation
  • TOP SELLING DRUGS IN ONCOLOGY SEGMENT OF IMMUNOTHERAPEUTICS GLOBAL MARKET, (2013-2021) ($MN)
  • 5.1 INTRODUCTION

Immunotherapy is the treatment given to suppress or amplify the immune response of a person using immunomodulators. The amplification of immune response is called as activation immunotherapy and the suppression of the immune response is called suppression immunotherapy. The global immunotherapeutics market is divided based on the segments,...

  • Cancer
  • Monoclonal Antibody
  • Therapy
  • AbbVie Inc.
  • Celgene Corporation
  • MARKET PENETRATION OF VARIOUS MULTIPLE MYELOMA DRUGS MANUFACTURERS WORLDWIDE (2016)
  • KEY MARKET HIGHLIGHTS

You can easily book an appointment with one online.

  • Cancer
  • Therapy
  • Amgen Inc.
  • Celgene Corporation
  • Takeda Pharmaceutical Company Limited
  • Pipeline portfolio
  • Market trends

It is used to treat breast cancer, non-small cell lung cancer, pancreatic cancer, and gastric cancer.

  • Blood Disease
  • Cancer
  • Celgene Corporation
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • PRESS RELEASE 6
  • COMPANY PRESS RELEASES RELATED TO VIDAZA

TS-## (tegafur, gimeracil, oteracil) ##.

  • Blood Disease
  • Cancer
  • Leukemia
  • Celgene Corporation
  • Nippon Shinyaku Co., Ltd.
  • 11.1 BIBLIOGRAPHY

MOLECULAR CANCER; ##(##): ##.

  • Cancer
  • Hospital
  • Therapy
  • World
  • Celgene Corporation
  • Phase I/II
  • 7. MARKET FORECAST AND OPPORTUNITY ANALYSIS

Effects of valproic acid in combination with S-## on advanced pancreatobiliary tract cancers: clinical study phases I/ II.

  • Cancer
  • Clinical Trial
  • Lymphoma
  • Therapy
  • Celgene Corporation
  • MAINTENANCE THERAPIES REPRESENT AN EMERGING TREATMENT SETTING FOR DLBCL
  • CLINICAL AND COMMERCIAL ATTRACTIVENESS

Cancer Research, ##(##), ##-## < PMID> ##< / PMID>.

  • Cancer
  • European Union
  • Japan
  • United States
  • Celgene Corporation
  • CLINICAL AND COMMERCIAL ATTRACTIVENESS
  • REVLIMID AND VELCADE ARE GENERATING SOME SALES FROM OFF-LABEL USAGE IN JAPAN

Clinical Cancer Research, ##(##), ##-## < DOI> ##. ##/ ##- ##.

  • Cancer
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • Celgene Corporation